Short Interest in Profusa, Inc. (NASDAQ:PFSA) Grows By 1,666.7%

Profusa, Inc. (NASDAQ:PFSA) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 665,135 shares, a growth of 1,666.7% from the April 15th total of 37,649 shares. Based on an average trading volume of 2,488,159 shares, the days-to-cover ratio is presently 0.3 days. Currently, 17.0% of the company’s shares are short sold.

Profusa Stock Performance

Shares of NASDAQ:PFSA traded down $0.04 during trading on Monday, reaching $0.48. The stock had a trading volume of 191,698 shares, compared to its average volume of 1,591,315. The business’s fifty day moving average is $0.74. Profusa has a 52 week low of $0.41 and a 52 week high of $180.00.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Profusa in a report on Friday, March 27th. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.